Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
22.05
+0.21 (0.96%)
Nov 22, 2024, 4:00 PM EST - Market closed
Jasper Therapeutics Employees
Jasper Therapeutics had 45 employees as of December 31, 2023. The number of employees increased by 10 or 28.57% compared to the previous year.
Employees
45
Change (1Y)
10
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$1,411,756
Market Cap
330.78M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45 | 10 | 28.57% |
Dec 31, 2022 | 35 | 10 | 40.00% |
Dec 31, 2021 | 25 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Cross Country Healthcare | 13,131 |
Viemed Healthcare | 996 |
Spok Holdings | 384 |
Kamada | 378 |
AVITA Medical | 207 |
AC Immune | 161 |
Sanara MedTech | 108 |
Design Therapeutics | 58 |
JSPR News
- 4 days ago - Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma - Seeking Alpha
- 9 days ago - Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - GlobeNewsWire
- 5 weeks ago - Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga
- 5 weeks ago - Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewsWire
- 2 months ago - Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma - GlobeNewsWire
- 2 months ago - Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences - GlobeNewsWire